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M
odern imaging techniques enable researchers to observe drug actions and consequences as they occur and persist in 
the brains of abusing and addicted individuals. This article presents the five most commonly used techniques, explains
how each produces images, and describes how researchers interpret them. The authors give examples of key findings illustrating
how each technique has extended and deepened our knowledge of the neurobiological bases of drug abuse and addiction, and
they address  potential clinical and therapeutic applications.
Imaging the Addicted Human Brain 
S
cientific advances over the last quarter century have established that drug
addiction is a chronic brain disease (Leshner, 1997). Key evidence for
this view consists of images of people’s brains taken during or following
drug exposures. Brain imaging studies have provided  information on drugs’ neu-
robiological effects, helped explain the causes and mechanisms of vulnerability to
drug abuse, and yielded important insights into abusers’ subjective experiences
and behaviors, including their struggles in recovery. Clinicians may one day—
perhaps sooner rather than later—use brain imaging to assess addiction, to assign
patients to appropriate care interventions, and to monitor response to therapy.
The five primary brain imaging techniques—structural magnetic resonance
imaging (MRI), functional  MRI, magnetic resonance spectroscopy (MRS),
positron emission tomography (PET), and single photon emission computed
tomography (SPECT)—reveal different aspects of brain structure or function
(Table 1). Individually, the techniques yield knowledge of brain anatomy and tis-
sue composition; biochemical, physiological, and functional processes; neuro-
transmitter activity; energy utilization and blood flow; and drug distribution and
kinetics. Together and in combination with other research techniques, they inform
a multidimensional understanding of the complex disease that is drug abuse and
addiction.
STRUCTURAL MRI 
What It Tells
Structural MRI provides information on the location, shapes, and sizes of the
brain’s various regions and subregions (Figure 1). It also can demonstrate the pres-
ence of abnormal tissue and changes in tissue composition. 
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What It Shows
A structural MRI image is a picture of water molecules
in a cross section or area of the brain. The technique
takes advantage of the fact that different types of tissues
contain different amounts of water. For example, of the
two types of tissues that make up most of the brain, gray
matter, which comprises mostly cell nuclei, is roughly
80 percent water, while white matter, which consists
mainly of connecting fibers between cells, is about 70
percent water (Neeb, Zilles, and Shah, 2005). Structural
MRI images show these differences in the water content
as different tones of gray. To make structures of interest
stand out better, scientists often use contrast agents to
heighten the differences. Scientists reading an MRI can
readily distinguish gray and white matter and other types
of tissue—both normal, such as blood vessels, and abnor-
mal, such as tumors—by their different shading and
contrast with surrounding areas (Figure 2).
How It Works
An MRI machine can be compared to a camera, but one
that registers radiofrequency energy reflected from the
hydrogen atoms in water molecules instead of light from
visible objects. The machine itself supplies the radiofre-
quency energy, somewhat analogous to the way a cam-
era flashbulb bounces light off a scene and then captures
the reflected light on film.
First, the machine generates a powerful magnetic
field that pulls the protons at the centers of all the brain’s
hydrogen atoms into alignment, like tops all spinning
straight up on their points(Figure 2). Next, the machine
emits a brief pulse of radiofrequency energy. The pro-
tons absorb this additional energy, which causes some
of them to “resonate”—that is, to realign at an angle
oblique to the magnetic field, like tops spinning on a
tilt. For the fraction of a second that the pulse lasts, this
subset of protons holds on to the energy. When the pulse
ends, they shed it.
The machine’s detection apparatus and computers
pinpoint the source of every packet of emitted energy—
in other words, the location of each hydrogen atom that
resonated. Even though all protons do not resonate,
enough do—out of the tens of billions in the brain—
so that registering all their locations in the image pro-
duces a highly detailed map of the brain’s tissues and
structures.
FIGURE 1. Major brain regions with roles in addiction 
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TABLE 1.  Brain imaging techniques used in drug abuse research 
IMAGING 
TECHNIQUE
PRINCIPAL 
APPLICATIONS
Structural magnetic 
resonance imaging
(MRI)
Map tissue mor-
phology, composi-
tion   
Magnetic resonance 
spectroscopy
(MRS)
Measure cerebral
metabolism, physio-
logical processes
involving 
specific brain 
chemicals; detect
drug metabolites
Positron emission 
tomography
(PET)
Quantify biochemi-
cal and pharma-
cological processes,
including glucose
metabolism; drug
distribution and
kinetics; receptor-
ligand interaction;
enzyme targeting
Single photon 
emission computed  
tomography 
(SPECT)
Measure receptor-
ligand interaction, 
physiological 
function, biochemi-
cal and pharmaco-
logical processes
Functional magnetic
resonance imaging
(fMRI)
Visualize changes in
oxygenation and
blood flow associ-
ated with brain activ-
ities
The prefrontal cortex is the focal area for cognition and planning. The ventral tegmental
area (VTA) and nucleus accumbens (NAc) are key components of the brain’s reward 
system. The VTA, NAc, amygdala, and hippocampus are major components of the limbic
system, which coordinates drives, emotions, and memories.
Frontal cortex
Basal ganglia
OFC OFC
VTA
Parietal 
cortex
Prefrontal
cortex Prefrontal
cortex
Cingulate gyrus
Nucleus
accumbens
Amygdala
Hippocampus
OFC= Orbitolfrontal cortex
VTA= Ventral tegmental area6 • SCIENCE & PRACTICE PERSPECTIVES—APRIL 2007
Insights From Structural MRI
Structural MRI studies have demonstrated that chronic
drug exposure can enlarge or shrink some regions of the
brain. These findings have helped scientists home in on
the regions where drugs exert important effects. They
often serve as starting points for further investigations,
using other research tools and techniques, to determine
the reasons for the volume changes and their conse-
quences for individuals’ thinking, feeling, and behavior.
Volume Changes in Frontal Cortex
The frontal cortex is a brain region that supports logical
thinking, goal setting, planning, and self-control. Numerous
MRI studies have documented that addictive drugs cause
volume and tissue composition changes in this region
and that these changes are likely associated with abusers’
cognitive and decisionmaking problems.
Polysubstance effects:A structural MRI study found that
individuals with a history of abusing multiple substances
have smaller prefrontal lobes than matched controls (Liu
et al., 1998). This finding adds to growing evidence asso-
ciating prefrontal abnormalities with abuse of various
substances (Stapleton et al., 1995; Volkow et al., 1991).
Using structural MRI, Schlaepfer and colleagues (2006)
found that chronic substance abusers’ frontal lobe tis-
sues contained a lower proportion of white matter than
those of matched controls. Similar white matter deficits
have been found in individuals with other psychiatric
disorders that tend to co-occur with substance abuse
(Schlaepfer et al., 2006).
Stimulants: Kim and colleagues (2005) documented a
reduction in gray matter density in the right middle
frontal cortex of abstinent methamphetamine abusers
(Figure 3). Lower density correlated with more errors
on the Wisconsin Card Sorting Task, which tests a
person’s ability to switch mental gears. Gray matter was
closer to normal in individuals who had been abstinent
for more than 6 months than in others with a shorter
period of abstinence. In another structural MRI study,
cocaine abusers who had been abstinent for 20 days
exhibited reduced gray matter density in regions of the
frontal cortex. No differences were found with respect
to white matter density (Matochik et al., 2003).
Alcohol:Investigators using structural MRI have reported
diminished cortical gray matter, most prominently in
the prefrontal cortex (PFC), in alcoholic patients in treat-
ment (Pfefferbaum et al., 1998). In another study,
researchers showed that alcohol-dependent individuals
had reduced whole brain, prefrontal cortical, and pari-
etal cortical gray matter compared with controls (Fein
et al., 2002).
Two studies have shown alcoholics’ frontal cortex
and other structures beginning to recover their normal
volumes within weeks of stopping drinking (Bendszus
et al., 2001; Pfefferbaum et al., 1995; see also O’Neill,
Cardenas, and Meyerhoff, 2001. For a good review on
brain imaging in alcoholism, see Mann et al., 2001.).
Volume Changes in Other Brain Structures
Several structural MRI studies have shown enlargement
of the brain’s basal ganglia in cocaine-dependent (Jacobsen
et al., 2001) and methamphetamine-dependent (Chang
et al., 2005a; Jernigan et al., 2005) subjects compared
with healthy subjects. This is similar to enlarged basal
ganglia structures seen in schizophrenic patients who
FIGURE 2. Making a magnetic resonance image
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1. The MRI machine gener-
ates a powerful magnetic
field, pulling the protons in
the brain’s hydrogen atoms
into alignment.
2. The machine emits a pulse
of radiofrequency (RF)energy.
Some protons absorb the
energy and tilt (resonate).
3. When the RF pulse ends,
the resonating protons shed
the absorbed energy and
jump back into alignment;
the shed energy strikes the
machine’s sensors.
4. Based on the amount and
direction of energy striking
the sensors, the machine’s
computer calculates the posi-
tion of each proton that res-
onated.
5. The computer generates a map
of the proton positions in a cross
section of the brain. Areas of
thicker or thinner proton density
indicate different tissue types. 
MRI image
Sensor Sensor
Magnet
Magnetic
field
RF pulse
Energy
Energy
Proton
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have been treated with typical antipsychotic medica-
tions (Gur et al., 1998). Because typical antipsychotics
and psychostimulants both lead to occupation of dopa-
mine receptors in the basal ganglia—the former directly
and the latter indirectly, through releasing dopamine—
these findings suggest the dopamine and basal ganglia
structures are involved in the psychoses that occur in
schizophrenia and in psychostimulant abuse.
An analysis of MRI images disclosed that a group of
chronic methamphetamine abusers had severe gray mat-
ter deficits in the cingulate, limbic, and paralimbic cor-
tices. They also had smaller hippocampi than nonabusers
of drugs. The hippocampus is a key site for memory stor-
age, and the volume decrements correlated with poorer
performance on a word recall test (Thompson et al.,
2004).
Another MRI study indicated that the amygdala, a
brain structure that helps shape our emotional responses
to experiences, is relatively small in children of alcoholics
(Hill et al., 2001). This finding might be a clue to the
brain sources of vulnerability to alcohol abuse disorders.
FUNCTIONAL MRI
What It Tells
Researchers read functional MRI images as maps of cel-
lular activity levels in a cross section or area of the brain.
In functional MRI studies, researchers compare mul-
tiple images, which may be of a single individual or dif-
ferent individuals.
Studies of a single individual taken under varying
conditions—for example, at rest and then working on
a puzzle, or before and after taking a drug—enable
researchers to map which brain regions he or she acti-
vates to perform mental tasks (e.g., puzzle solving) or in
response to experiences or chemical exposures. Studies
of individuals from different groups—for example, 
drug-addicted and nonaddicted—can reveal differences
in the brain regions the two groups use to perform iden-
tical tasks or respond to stimuli or exposures.
What It Shows
What a functional MRI machine actually detects are
changes in the local magnetic field that occur as a result
of changes in the ratio of oxygenated to deoxygenated
hemoglobin in arterial blood vessels in specific brain
regions during a cognitive task. The rationale for inter-
preting these changes as cellular activity is that cells in
the brain, like those elsewhere in the body, use oxygen
as fuel. As they increase their activity, they increase their
demand for oxygen, and the arterial blood vessels respond
by delivering more oxygenated hemoglobin to the region.
How It Works
Like structural MRI, functional MRI produces images
by applying a magnetic field and detecting radiofre-
quency energy from the protons in water molecules.
However, functional MRI exploits two additional facts,
one biological and one physical:
• Biologically, the more oxygen that cells in a region uti-
lize, the more oxygen-carrying hemoglobin molecules
will be found in the blood vessels responsible for sup-
plying them.
• Physically, hemoglobin molecules that have oxygen
molecules attached to them and those that do not exert
measurably different effects on the magnetic prop-
erties of surrounding tissues.
By tuning the magnets and energy pulses of the MRI
machine to capture these differences, researchers pro-
duce images in which differences in oxygen content show
up as variations in tone or color. This is called blood
oxygen level dependent, or BOLD, contrast.
Insights From Functional MRI
The differences in brain activity patterns revealed by
functional MRI provide invaluable information on a
range of issues. Studies have correlated regional brain
patterns in response to taking a drug with vulnerability
to drug abuse, addictive symptoms and behaviors, and
long-term cognitive capacity.
Stimulant Effects Correlate With Brain Activity in
Several Areas
Researchers have used functional MRI to obtain detailed
information about the roles of different brain areas in
producing cocaine-induced euphoria and subsequent
craving. In one investigation, volunteers given an infu-
FIGURE 3. MRI: Methamphetamine reduces gray matter  
The yellow and red area in the central brain view indicates reduced gray matter density 
in the right middle frontal cortex (Kim et al., 2005). The same deficit is shown from other 
perspectives in the flanking views. 8 • SCIENCE & PRACTICE PERSPECTIVES—APRIL 2007
sion of cocaine reported a drug rush during the brief
period when a set of areas, including the caudate (an area
of the basal ganglia), cingulate, and most of the lateral
PFC showed higher levels of activity. The participants’
reports of craving commenced when the euphoria
subsided and persisted as long as a different set of
brain areas—including the nucleus accumbens (NAc)—
remained activated (Breiter et al., 1997; Breiter and
Rosen, 1999). Two more recent studies also saw corre-
lations between craving and NAc activity, although—
possibly because of differences in study methods—
the “high” was associated with decreased rather than
increased brain activity in regions including the NAc,
inferior frontal/orbitofrontal gyrus, and anterior cin-
gulate. Craving correlated positively with activity in these
regions (Kufahl et al., 2005; Risinger et al., 2005). 
Other functional MRI studies have demonstrated that
cocaine-addicted individuals’ vulnerability to cocaine-
related cues has a neurological basis. For example, Wexler
and colleagues (2001) documented activation of the ante-
rior cingulate cortex, a region associated with emotional
processing, while cocaine-addicted subjects watched video-
tapes containing cocaine-associated cues, even if they did
not experience
craving (Figure
4). The finding 
indicates that
addicted indi-
viduals’ emo-
tional responses
to cues have a
subconscious
component. The
subjects also
showed less acti-
vation in the
frontal lobe than
healthy subjects
during the cocaine cue tapes, suggesting that their ability
to control their cue responses was inhibited. Research with
functional MRI has linked chronic stimulant abusers’ cog-
nitive impairments to drug-related alterations in brain
activation. In one study, methamphetamine dependence
and poor decisionmaking correlated with reduced acti-
vation in the PFC (Paulus et al., 2002). In another, inves-
tigators discovered that chronic cocaine abusers had abnor-
mally low levels of activity in midline areas of the anterior
cingulate that are crucial for cognitive and behavioral con-
trol (Kaufman et al., 2003).
Genes Affect Responses to Drugs and Vulnerability
to Abuse
Innovative functional MRI studies recently have begun
to explore the role of genes in drug abuse. In one, a gene
variation that affects the metabolism of neurotransmit-
ters, including dopamine and norepinephrine, appeared
to influence the brain’s response to amphetamine (Mattay
et al., 2003). A similar functional MRI study discovered
that individuals with a particular variation in the sero-
tonin transporter gene experienced greater activation in
the amygdala, a region associated with fear and anxiety,
in response to fearful stimuli (Hariri et al., 2002). This
genetic variation could increase sensitivity to stress
and heighten vulnerability to drug abuse.
MAGNETIC RESONANCE SPECTROSCOPY
What It Tells
In addition to creating structural and functional maps
of the brain, magnetic resonance technology can be used
to detect and measure important chemical contents
within the brain. To be visible in an MRS image, a chem-
ical must respond in a unique way to magnetization and
energy stimulation, and it must be present in relatively
high concentrations (in the millimolar range).
What It Shows
MRS scans reveal the location and concentrations of tar-
get chemicals in the brain tissues (Ross, Kreis, and Ernst,
1992). Among chemicals naturally present in the brain,
two that can be studied with MRS include N-acetylas-
partate (NAA), which researchers use as a gauge of neu-
ronal cell health (Birken and Oldendorf, 1989), and
myoinositol, which is primarily present in support cells,
called glia (Brand, Richter-Landsberg, and Leibfritz,
1993), and thus provides an index of the health of
glial cells. Other molecules that can be detected easily
are choline compounds, which are involved in the turnover
of cell membranes, and creatine compounds, which are
important for cells’ energy maintenance. Among sub-
stances of abuse that penetrate the brain after being
ingested or administered, alcohol is readily apparent
with MRS (Hetherington et al., 1999).
How It Works
MRS, like functional MRI, follows the basic steps of
structural MRI, but uses different scanner settings. In
MRS, the magnetic pulses and radiofrequency energy
are used to stimulate the nucleus of particular elements
(e.g., hydrogen-1, carbon-13, phosphorous-31, or flu-
FIGURE 4. Functional MRI: The brain’s response to
cocaine cues  
Arrows point to the anterior cingulate area, which is activated 
(yellow) in cocaine-addicted patients (left) but not in healthy 
volunteers (right) (Wexler et al., 2001).RESEARCH REVIEW—IMAGING THE ADDICTED HUMAN BRAIN • 9
orine-19) that are present in metabolites of interest
throughout the brain. The sum of all these signals is
recorded and then analyzed using specialized computer
programs to separate the signals corresponding to
each metabolite. The results can be displayed as various
metabolite peaks on a spectrum. 
Insights From MRS
Researchers have used MRS to identify drug-related
biochemical changes that indicate damage to the health
and function of brain cells. Often, these studies focus
on brain areas that preclinical models or other studies
of the neuropathology of drug abusers have shown to
be affected. In some cases, biochemical changes have
been directly correlated with cognitive and behavioral
deficits.
A central finding of MRS studies has been that drugs
affect markers associated with inflammation, brain energy
metabolism, and neuronal health. For example, Ernst
and colleagues (2000) showed that methampheta-
mine abusers had reduced NAA concentrations in their
basal ganglia and frontal white matter, compared with
nonabusers of drugs. This finding could help explain
the cognitive difficulties experienced by methamphet-
amine abusers; concentrations of NAA have corre-
lated with measures of cognitive function even in healthy
nondrug users (Rae et al., 1998).
Cocaine-dependent individuals also have been found
to have decreased NAA levels, suggesting neuron
damage, as well as elevated creatine and myoinositol lev-
els reflecting increased glial cell activity or inflamma-
tion (Chang et al., 1999).
Other research has evaluated interactions between
HIV and drugs of abuse on brain metabolites. For exam-
ple, a study found that methamphetamine abuse and
HIV decreased brain NAA additively, especially in the
striatum, while choline and myoinositol were further
elevated in the frontal lobes (Chang et al., 2005b).
Chronic marijuana use and HIV infection are each sep-
arately associated with lower levels of glutamate; together,
they appear to moderate glutamate loss in the frontal
white matter while exacerbating it in the basal ganglia
(Chang et al., 2006).
Magnetic resonance techniques, including MRS, are
especially useful for studying the effects of drugs in
the pediatric population because they do not involve
radiation. Smith and colleagues (2001a, 2001b) con-
ducted MRS studies of children who had been exposed
to cocaine or methamphetamine prenatally and found
that their total brain creatine levels were elevated, 
suggesting abnormalities in energy metabolism.
NUCLEAR MEDICINE IMAGING TECHNIQUES
PET and SPECT are called “nuclear medicine tech-
niques” because they require injecting molecules labeled
with radioactive isotopes into the bloodstream of the
person being studied. Because the half-lives of the iso-
topes are short, the radiation dose is small, on the order
of other medical diagnostic procedures, and studies can
be carried out in healthy volunteers as well as in drug-
addicted patients. However, PET and SPECT are not
normally used in healthy children.
What They Tell
PET and SPECT, like MRS, map the presence of spe-
cific molecules in the brain. These techniques are par-
ticularly valuable in drug abuse research because they
can measure concentrations of molecules that are 
extremely low—in the nanomolar and picomolar range,
one millionth to one billionth the minimum amounts
necessary for visibility in MRS (Fowler, Ding, and 
Volkow, 2003; Kung, Kung, and Choi, 2003). This level
of sensitivity enables researchers to study drugs’ effects
on key components of cell-to-cell communication,
including cell receptors, transporters, and enzymes
involved in the synthesis or metabolism of neurotrans-
mitters (Volkow, Fowler, and Wang, 2003a).
Researchers also use PET to study drug pharmaco-
kinetics: A series of images taken at appropriate inter-
vals provides a stop-action record of a drug’s movement
into and out of the brain, showing how much enters the
brain, where it binds in the brain, and how long it remains
(Fowler et al., 1999). This information is crucial because
the rate at which a drug enters the brain largely deter-
mines its euphoric effects and addictiveness. PET can
also assess rates of glucose metabolism, complementing
functional MRI measurement of changes in blood oxy-
gen levels for determining cellular activity. A common
use for SPECT is to measure brain blood flow.
What They Show
A PET or SPECT image displays the distribution of a
labeled compound, called a radiotracer, that travels to
the brain and other organs after being injected into
the bloodstream. A radiotracer consists of two linked
components: 
• a carrier chemical, usually an organic compound or
drug, whose properties determine where the radio-10 • SCIENCE & PRACTICE PERSPECTIVES—APRIL 2007
tracer goes once it reaches the brain; and 
• a radioactive isotope, which is bound to, or “labels,”
the carrier chemical and emits energy as products of
its radioactive decay.
The emitted energy interacts with detectors in the
PET or SPECT instrument. The instrument’s comput-
ers register the location of the radioisotope and use
this information to calculate and map the radiotracer’s
distribution in the brain or body.
How They Work
PET and SPECT are similar technologies. As their names
suggest, their differences relate mainly to their use of dif-
ferent types of isotopes in their radiotracers. 
PET radiotracers incorporate isotopes that emit beta
positron (ß+) radiation. One especially important set of
PET radiotracers incorporates positron-emitting iso-
topes of the chemical elements of life—carbon, oxygen,
and nitrogen—into organic compounds in place of the
naturally occurring nonradioactive elements. Substituting
radioactive carbon-11 for nonradioactive carbon-12
in a drug molecule, for example, does not change the
drug’s behavior in the brain, but does make it visible on
PET imaging (Figure 5). 
One uniquely valuable PET tool is 2-deoxy-2-[18F]
fluoro-D-glucose (18FDG), a radiotracer used to meas-
ure brain glucose metabolism. 18FDG consists of a glu-
cose molecule in which the radioactive isotope fluorine-
18 has been substituted for the naturally occurring
hydroxyl group (Fowler and Ido, 2002). PET’s ability
to produce an image of glucose metabolism in the brain
using 18FDG is a major advantage, as glucose, along
with oxygen, is a major source of the organ’s energy.
Many PET studies have explored the role of the neu-
rotransmitter dopamine in drug abuse and addiction.
The radiotracers for these studies use as carrier com-
ponents chemicals that bind to dopamine-related struc-
tures on brain cells, including dopamine receptors,
dopamine transporters, and dopamine-degrading and
synthetic enzymes (Halldin et al., 2001; Rinne et al.,
1995; Volkow et al., 1995, 1996a; Wong et al., 1993).
SPECT radiotracers are labeled with single photon
emitting radioisotopes. The most commonly used are
iodine-123 and technetium-99m.
Insights From Nuclear Medicine Imaging
Techniques
PET and SPECT brain imaging have perhaps shown
their greatest value to date in helping researchers ana-
lyze how drugs affect the neurotransmitter systems that
link and coordinate brain cells. Much of this work has
focused on the dopamine system, but researchers also
are exploring the roles of other neurotransmitters in drug
abuse and drugs’ effects on cells’ energy consumption
and health.
Dopamine Plays Key Roles in Drug Abuse Euphoria
and Addiction
The neurotransmitter dopamine is highly concentrated
in the striatum, which forms part of the brain’s reward
system. Dopamine ebb and flow in these areas is a main
determinant of how much pleasure we derive from
our experiences; it also helps us focus our attention on
what is important. PET studies have linked the presence
and actions of drugs of abuse in the brain’s reward sys-
tem with their euphoric properties and their ability to
preoccupy addicted individuals to the exclusion of nat-
urally rewarding activities (Di Chiara, 1999; Di Chiara
and Imperato, 1988; Leshner, 1997; Volkow, Fowler,
and Wang, 2003b).
In one study, researchers administered carbon-11-
labeled cocaine to drug abusers who had refused treat-
ment (a requirement for ethical review board approval)
and used PET imaging to track the movement of the
drug into and out of the brain while the abusers reported
the intensity of their highs. The results showed that the
FIGURE 5. Creating radiotracers for PET imaging   
(A) Chemists replace a naturally occurring carbon 12 atom in the cocaine molecule with a
carbon 11 atom to make [11C] cocaine, a radiotracer that acts just like natural cocaine 
in the body and brain. [11C] cocaine decays by positron emission, resulting in two ener-
getic photons that are detected by a PET scanner to produce an image of glucose metabo-
lism in the brain. (B) Chemists replace a hydroxyl (-OH) group on the glucose molecule
with fluorine-18 to make 18FDG, a radiotracer which is used to measure brain glucose
metabolism. 
11C  for 12C
= O
= N
= H
= C 
A. B.
18F  for 19Ftransporters, which may indicate a loss of dopamine cells
(Volkow et al., 2001b). Study participants with fewer
dopamine transporters had poorer memory and slower
motor function.
Stimulants Reduce Cellular Activity in Brain Areas
Affecting Judgment
PET studies have explored cocaine’s impact on brain
structures and activity, and their relationship to addicted
individuals’ ability to function during and after treat-
ment. Among important results in this line, studies have
shown that cocaine (Volkow et al., 1993) and metham-
phetamine (Bolla et al., 2003; Volkow et al., 2001a)
reduce cellular activity in the orbitofrontal cortex (OFC),
a brain area we rely on to make strategic, rather than
impulsive, decisions (Figure 8). Patients with traumatic
injuries to this area of the brain display problems—
aggressiveness, poor judgment of future consequences,
inability to inhibit inappropriate responses—that are
similar to those observed in substance abusers (Bechara
et al., 1994, 2001; Eslinger et al., 1992). The radiotracers
used in these studies were 18FDG and oxygen-15 water,
which measure the brain’s consumption of its two main
fuels, glucose and oxygen (Raichle et al., 1983).
Bolla and colleagues (2003) demonstrated the link
between lower metabolism in the OFC and cocaine
abusers’ poor judgment. The researchers took serial PET
images, using oxygen-15 water as the radiotracer, while
FIGURE 7. PET: Cocaine causes dopamine buildup in the synapse  
In this illustration based on PET studies, cocaine blocks the dopamine transporter, 
preventing it from pulling dopamine back into the sending cell. As a result, dopamine
molecules accumulate in the intercellular space, striking the receiving cell’s receptors 
and causing an intensified response within the receiving cell.
Dopamine
Signal
Transporter
Cocaine
Dopamine
receptors
A. B.
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high spiked and subsided in tandem with cocaine’s move-
ment in and out of the striatum (Volkow et al., 1997;
Figure 6). Using the same experimental design with dif-
ferent radiotracers, PET and SPECT investigators estab-
lished that cocaine, amphetamine, and methylphenidate,
when given intravenously, produce their highs by mas-
sively increasing the amount of dopamine in the stria-
tum (Drevets et al., 2001; Laruelle et al., 1995; Volkow
et al., 1999). Previous studies with animals had suggested
that this was probably the case, but nuclear medicine
imaging enabled researchers to noninvasively document
the correlation as it actually occurred in living people.
Still other PET studies have shown that any drug’s abuse
liability depends both on the size of the dopamine spike
it produces and the rapidity with which dopamine rises
and falls back to normal levels.
PET experiments have identified how one drug,
cocaine, causes dopamine to surge: The drug inter-
feres with the normal activity of molecules called dopamine
transporters on brain cell surfaces (Figure 7). By doing
so, it disrupts the equilibrium of dopamine release and
reuptake that maintains levels of the neurotransmitter
within normal limits.
Chronic Methamphetamine Abuse Depletes
Dopamine Function
A PET study revealed that while methamphetamine
temporarily hyperactivates the dopamine system, chronic
exposure to the drug reduces the availability of dopamine
FIGURE 6. PET: Cocaine activity in the striatum
underlies the cocaine high 
After study subjects were given [11C] cocaine, PET showed that
their reports of how high they felt rose and fell in very close paral-
lel with the passage of the drug in and out of the brain area called
the striatum (Volkow et al., 1997).
time (min)
high
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cocaine abusers who had been abstinent for 25 days played
a card game on a computer. Players who had used more
cocaine before abstaining demonstrated less OFC activ-
ity, and they performed more poorly during the game.
Dopamine Receptor Levels May Determine
Vulnerability to Abuse and Addiction
PET studies have demonstrated that abusers of alco-
hol (Volkow et al., 1996b), cocaine (Volkow et al., 1990,
1993), heroin (Wang et al., 1997), and methampheta-
mine (Volkow et al., 2001a) all have reduced levels of
brain dopamine receptors—the proteins on cell surfaces
that dopamine activates to stimulate cellular activity
(Figure 9). These findings, together with other evidence,
have given rise to a hypothesis that people with low lev-
els of these receptors, either genetically or as a result of
their experiences, have a higher risk of drug abuse and
addiction. Scientists speculate that such individuals
obtain less than normal amounts of dopamine-
mediated pleasure from ordinary activities and accom-
plishments and therefore are highly susceptible to want-
ing to repeat the euphoria that occurs when drugs mas-
sively increase dopamine in the brain.
The Mu-opioid System Plays a Role in Cocaine
Craving
PET studies have suggested that the symptoms of cocaine
dependence and craving may be caused at least in part
by the drug’s effects on another neurotransmitter sys-
tem, the mu-opioid system. In one study (Zubieta et al.,
1996), cocaine-addicted individuals who entered a clinic
to quit the drug and remained there for a month of mon-
itored abstinence filled out assessments of their mood
and craving symptoms and underwent PET scans, once
during their first 4 days in the clinic and again toward
the end of the month. Using a radiotracer whose carrier
component is an opioid medication (carbon-11 car-
fentanil), researchers found that the participants’ symp-
tom severity correlated with mu-opioid receptor levels
in several brain areas. In interpreting their findings, the
researchers suggested that cocaine may deplete the body’s
natural opioids, and the body may try to compensate by
generating more receptors or increasing existing recep-
tors’ readiness to bind to opioid molecules.
Nicotine Is Not the Sole Culprit in Tobacco
Addiction
PET imaging studies have affirmed the importance of
dopamine in nicotine abuse and addiction (Brody et al.,
2004) and also highlighted the need to investigate the
other chemicals in tobacco smoke. Recent studies
have found that one or more components of tobacco
smoke reduces levels of monoamine oxidase (MAO)
in the brain and throughout the body (Fowler et al.,
1996a, 1996b, 2003a, 2003b, 2005; Figure 10). MAO
is an enzyme that breaks down neurotransmitters; its
two forms, MAO-A and MAO-B, perform different
functions although both break down dopamine. One
consequence of MAO inhibition by tobacco smoke may
be exacerbation of the nicotine-induced dopamine dys-
regulation that reinforces the desire to smoke as well as
to abuse other substances. Consistent with this idea,
recent preclinical studies show that inhibiting MAO-A
enhances nicotine self-administration in animals
The striatum of the healthy control (left) is largely red, indicating
the highest level of receptor availability, while that of the cocaine
abuser has little red.
FIGURE 9. PET: Cocaine markedly reduces
dopamine D2 receptor availability
FIGURE 8. PET: Cocaine abusers have reduced metabolism in the
orbitofrontal cortex
In this comparison of a healthy subject (left) and a cocaine abuser, red represents the high-
est and blue and purple the lowest level of metabolic activity, as measured by 18FDG.RESEARCH REVIEW—IMAGING THE ADDICTED HUMAN BRAIN • 13
(Guillem et al., 2006). In contrast, in a recent trial using
the selective MAO-B inhibitor selegiline, a dose of 10
mg/day safely enhanced smoking cessation rates com-
pared with placebo in nicotine-dependent cigarette
smokers (George et al., 2003).
The PET finding that smokers have low levels of
MAO sheds light on why smokers have a reduced risk
of Parkinson’s disease (Morens et al., 1995). When MAO
metabolizes dopamine, a byproduct is hydrogen per-
oxide, a potential source of free radicals that can dam-
age nerve cells. MAO-inhibiting chemical compounds
have been isolated from tobacco (Khalil, Steyn, and
Castagnoli, 2000) and shown to have protective actions
in a rodent model of Parkinson’s disease (Castagnoli et
al., 2002).
CLINICAL APPLICATIONS OF IMAGING
The information that magnetic resonance and nuclear
imaging studies have yielded on the brain dynamics of
addiction has become a primary source of medication
development strategies. Direct clinical applications are
still few, but recent studies suggest the techniques may in
the future enhance patient assessment and monitoring.
Medication Development
Imaging studies, together with other research, over-
whelmingly indicate that drug addiction must be viewed
as both a disease of changed brain biology and a behav-
ioral disorder. To be effective over the long term, treat-
ment should focus on enhancing and restoring disrupted
dopamine function and brain circuitry, and include
pharmacologic and behavioral approaches.
In the area of pharmacologic interventions in partic-
ular, imaging findings have suggested many avenues of
possible approach. One strategy under active investiga-
tion takes its cue from the PET finding that stimulant
drugs produce euphoria by causing a rapid dopamine
spike and, in doing so, reduce abusers’ ability to feel pleas-
ure when their other, nondrug-related activities cause
more modest, natural neurotransmitter elevations (see
Volkow et al., 2004, for a review). Researchers are iden-
tifying and testing medications that slightly increase the
amount of dopamine that cells release when a person
engages in normally rewarding activities in hopes that the
boost will enable addicted individuals to once again begin
to feel pleasure from them. MAO-B inhibitors and other
medications fitting this criterion have been used suc-
cessfully to treat smoking addiction (George et al., 2003).
Another medication strategy, also following from
imaging evidence that dopamine spikes underlie drug
euphoria, seeks to reduce the stimulant high and the
desire to repeat it by inhibiting the dopamine response
to these drugs. In one application of this strategy, researchers
are testing compounds that enhance the neurotransmit-
ter gamma-aminobutyric acid (GABA), which has been
shown to inhibit dopamine-releasing cells’ response to
drug-related cues (Di Ciano and Everitt, 2003); prelim-
inary clinical trials have yielded promising results (Brodie
et al., 2005; Brodie, Figueroa, and Dewey, 2003; Gonzalez
et al., 2003; Johnson et al., 2003). Other medications
interfere with the responses of dopamine-receiving
cells and thereby attenuate the reinforcing effects of 
abused drugs. For example, selective cannabinoid recep-
tor (CB1) antagonists have been shown to modulate both
dopamine-releasing and -receiving cell responses in pre-
clinical studies (De Vries et al., 2001; Julian et al., 2003).
A third strategy to counter drug-induced euphoria
and its hold over individuals utilizes a medication that
activates the same neurotransmitter system as an abused
drug, but produces no sharp dopamine spike. Treatment
of heroin addiction with methadone and buprenorphine
exemplifies this approach (Kreek, LaForge, and Butelman,
2002). Similar attempts to treat stimulant addiction
have not yet proved successful. Replacement of cocaine
with oral methylphenidate or oral amphetamine did not
decrease cocaine consumption when compared with
placebo in most drug-addicted individuals. However,
treatment with oral methylphenidate did decrease drug
consumption by patients suffering from comorbid addic-
tion and attention deficit hyperactivity disorder (Grabowski
FIGURE 10. PET: Smoking reduces an important
enzyme  
In these composite PET images of smokers and nonsmokers,
arrows demonstrate lower concentrations of the enzyme mono-
amine oxidase in many of the smokers’ organs (Fowler et al.,
2003b).et al., 1997; Shearer et al., 2003; Volkow, Fowler, and
Wang, 2004).
Patient Assessment and Monitoring
Recent studies suggest that imaging has the potential to
help clinicians determine the most appropriate level 
of treatment for individual patients and monitor their
progress toward recovery. Paulus, Tapert, and Schuckit
(2005) performed functional MRI on a group of men
entering treat-
ment for meth-
amphetamine
addiction while
they made deci-
sions during a
psychological test.
The results
revealed two 
contrasting pat-
terns of brain
activity that pre-
dicted with 90
percent accuracy
which of the
men would rel-
apse within 1 to
3 years after com-
pleting treat-
ment. Those
who relapsed
exhibited less
activity in the
prefrontal lobe and also in regions not previously noted
to play a role in addiction. Another study found that a
more rapid response of the posterior cingulate to cocaine
cues distinguished relapsers from nonrelapsers, even
though both groups reported similarly intense cravings
(Kosten et al., 2006).
Imaging researchers also have been documenting
changes that appear to represent brain recovery in response
to treatment. One group has applied MRS to evaluate
the effects of methadone maintenance therapy on heroin-
addicted individuals (Silveri et al., 2004). The subjects’
levels of certain metabolites involved in cellular energy
production were abnormal at the start of treatment and
changed over the first month. The researchers interpreted
the metabolite changes as evidence that the switch from
heroin to methadone might improve the neurons’
oxygen supply. This explanation may account for the
finding in another study by the same research group that
individuals’ cognitive abilities improve during their first
2 months of methadone therapy (Gruber et al., 2006).
Similarly, studies at Brookhaven National Laboratory
have shown that while detoxified methamphetamine
abusers have fewer dopamine transporters than age-
matched individuals never exposed to the drug, those
who remained abstinent for 9 months recovered a sig-
nificant portion of transporters (Volkow et al., 2001b).
Unfortunately, they did not have concomitant recovery
from the cognitive and motor deficits associated with
the low transporter levels. PET studies also showed sig-
nificant recovery in brain glucose metabolism in metham-
phetamine abusers after withdrawal (Wang et al., 2004)
(Figure 11).
CONCLUSION
Brain imaging techniques enable researchers to observe
drug effects while they are occurring in the brain and
compare brain structure, function, and metabolism in
drug-abusing and nonabusing individuals. The results
to date have firmly established that drug addiction is a
disease of the brain, causing important derangements
in many areas, including pathways affecting reward and
cognition. Ongoing studies continue to broaden our
understanding of the dynamics underlying the devel-
opment, symptoms, and consequences of addiction,
as well as recovery. Having given rise to several poten-
tial approaches to medication development, imaging
technologies are certain to become an increasingly impor-
tant source of clinical benefits.
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FIGURE 11. PET:  Brain recovery occurs with
methamphetamine abstinence 
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